Abcam logo

ABC - Abcam Share Price

1402p -13.0  -0.9%

Last Trade - 14/05/21

Large Cap
Market Cap £3.18bn
Enterprise Value £3.08bn
Revenue £269.3m
Position in Universe 240th / 1826
Unlock ABC Revenue
Relative Strength (%)
1m -0.98%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -19.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
144 171.7 217.1 233.2 259.9 260 317.5 343.1 +12.5%
+10.0 +10.0 +7.4 +84.8 -15.4 -31.5 -21.6 +26.6
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, Abcam Plcrevenues increased 7% to £147.5M. Net income decreased 55%to £11.7M. Revenues reflect an increase in demand for theCompany's products and services due to favorable marketconditions. Net income was offset by Selling/General/Admin.Expense increase of 26% to £70.5M (expense), R&D expensesexcluding share-based payme increase of 54% to £10.5M(expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for ABC
Graphical History


ABC Revenue Unlock ABC Revenue

Net Income

ABC Net Income Unlock ABC Revenue

Normalised EPS

ABC Normalised EPS Unlock ABC Revenue

PE Ratio Range

ABC PE Ratio Range Unlock ABC Revenue

Dividend Yield Range

ABC Dividend Yield Range Unlock ABC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
ABC EPS Forecasts Unlock ABC Revenue
Profile Summary

Abcam plc is a global life sciences company. The Company identifies, develops, and provides biological reagents and tools, which are required in a range of fields and applications including drug discovery, diagnostics and basic research. The Company’s solutions include research use only (RUO) proteomic tools and antibody development for clinical application. The RUO proteomic products include protein binding reagents, such as antibodies and immunoassays, and related reagents. The Company’s products are used by researchers to study biological pathways, which is critical for scientific research, diagnostics and drug discovery. The Company serves scientists and researchers in academic institutions, research institutes and pharmaceutical, biotechnology and diagnostics companies.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated February 12, 1998
Public Since November 3, 2005
No. of Shareholders: n/a
No. of Employees: 1,500
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , ,
Exchange London Stock Exchange (AIM)
Shares in Issue 226,742,614
Free Float (0.0%)
Eligible for
ABC Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ABC
Upcoming Events for ABC
Frequently Asked Questions for Abcam
What is the Abcam share price?

As of 14/05/21, shares in Abcam are trading at 1402p, giving the company a market capitalisation of £3.18bn. This share price information is delayed by 15 minutes.

How has the Abcam share price performed this year?

Shares in Abcam are currently trading at 1402p and the price has moved by 0.57% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abcam price has moved by -19.14% over the past year.

What are the analyst and broker recommendations for Abcam?

Of the analysts with advisory recommendations for Abcam, there are there are currently 0 "buy" , 7 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Abcam is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Abcam next release its financial results?

Abcam is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Abcam dividend yield?

Abcam does not currently pay a dividend.

Does Abcam pay a dividend?

Abcam does not currently pay a dividend.

When does Abcam next pay dividends?

Abcam does not currently pay a dividend.

How do I buy Abcam shares?

To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Abcam?

Shares in Abcam are currently trading at 1402p, giving the company a market capitalisation of £3.18bn.

Where are Abcam shares listed? Where are Abcam shares listed?

Here are the trading details for Abcam:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ABC
What kind of share is Abcam?

Based on an overall assessment of its quality, value and momentum, Abcam is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Abcam share price forecast 2021?

Shares in Abcam are currently priced at 1402p. At that level they are trading at 0.21% premium to the analyst consensus target price of 1,399.06.

Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of 0.18581 for the next financial year.

How can I tell whether the Abcam share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, the relative strength of its shares against the market has been -9.26%. At the current price of 1402p, shares in Abcam are trading at -2.78% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Abcam PE Ratio?

The Abcam PE ratio based on its reported earnings over the past 12 months is 96.28. The shares are currently trading at 1402p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Abcam?

Abcam's management team is headed by:

Alan Hirzel - CEO
Louise Patten - NID
Mara Aspinall - NID
Giles Kerr - NID
Marc Perkins - GCN
Michael Baldock - CFO
Chienling Lee - NED
Mark Capone - NED
Who are the major shareholders of Abcam?

Here are the top five shareholders of Abcam based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 9.08% (20.6m shares)
Milner (Jonathan Simon) Individual Investor
Percentage owned: 6.94% (15.7m shares)
Durable Capital Partners LP Hedge Fund
Percentage owned: 6.53% (14.8m shares)
Harding Loevner LP Investment Advisor
Percentage owned: 5.08% (11.5m shares)
Aberdeen Asset Managers Ltd. Investment Advisor/Hedge Fund
Percentage owned: 4.67% (10.6m shares)
Similar to ABC
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.